PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Merck’s Keytruda pulled from England’s Cancer Drugs Fund in bladder cancer

Merck’s Keytruda has suffered its second setback with English cost watchdogs in as many months. In final guidance, NICE rejected the drug in patients with locally advanced or metastatic urothelial carcinoma who have had platinum-containing chemotherapy.

The drug had been available via England’s Cancer Drugs Fund following an earlier review while authorities collected more evidence. But last week, the National Institute for Health and Care Excellence said it still couldn’t recommend the drug due to cost-effectiveness uncertainties.

As a result, the Merck immuno-oncology blockbuster will be pulled from the Cancer Drugs Fund. New patients won’t be able to start on the treatment, but those who are already receiving treatment may continue. 

The list price for the treatment is about £5,600 every three weeks, or £11,200 every six weeks.

The decision is particularly disappointing for Keytruda and patients because Keytruda was was the only med among its rivals to score even a Cancer Drugs Fund recommendation in the indication. Roche’s Tecentriq and BMS’ Opdivo each were rejected in bladder cancer in earlier NICE decisions. 

The NICE setback follows another for Keytruda last month. In draft guidance, the agency rejected the combo of Keytruda and Pfizer’s Inlyta in previously untreated kidney cancer patients. 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026